Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness

David Hoyos^#¹, Roberta Zappasodi^#^{2

3

4

5}, Isabell Schulze^{6

7}, Zachary Sethna^{1

8

9}, Kelvin César de Andrade¹⁰, Dean F Bajorin^{11

9}, Chaitanya Bandlamudi^{12

13}, Margaret K Callahan^{11

9}, Samuel A Funt^{11

9}, Sine R Hadrup¹⁴, Jeppe S Holm¹⁴, Jonathan E Rosenberg^{11

9}, Sohrab P Shah^{1

15}, Ignacio Vázquez-García¹, Britta Weigelt¹², Michelle Wu¹⁶, Dmitriy Zamarin^{6

11

9}, Laura F Campitelli¹⁷, Edward J Osborne¹⁷, Mark Klinger¹⁷, Harlan S Robins¹⁷, Payal P Khincha¹⁰, Sharon A Savage¹⁰, Vinod P Balachandran^{11

7

8

9

18}, Jedd D Wolchok^{6

11

7

19}, Matthew D Hellmann^{11

7

20}, Taha Merghoub^{21

22

23

24}, Arnold J Levine²⁵, Marta Łuksza²⁶, Benjamin D Greenbaum^{27

28}

Affiliations

¹ Computational Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Swim Across America Laboratory and Ludwig Collaborative, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. roz4022@med.cornell.edu.
³ Department of Medicine, Weill Cornell Medical College, New York, NY, USA. roz4022@med.cornell.edu.
⁴ Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. roz4022@med.cornell.edu.
⁵ Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA. roz4022@med.cornell.edu.
⁶ Swim Across America Laboratory and Ludwig Collaborative, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷ Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁸ Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁰ Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
¹¹ Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
¹² Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹³ Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁴ Experimental and Translational Immunology, Health Technology, Technical University of Denmark, Lyngby, Denmark.
¹⁵ Physiology, Biophysics & Systems Biology, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY, USA.
¹⁶ Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁷ Adaptive Biotechnologies, Seattle, WA, USA.
¹⁸ David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁹ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²⁰ Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²¹ Swim Across America Laboratory and Ludwig Collaborative, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org.
²² Department of Medicine, Weill Cornell Medical College, New York, NY, USA. merghout@mskcc.org.
²³ Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org.
²⁴ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org.
²⁵ Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ, USA.
²⁶ Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²⁷ Computational Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. greenbab@mskcc.org.
²⁸ Physiology, Biophysics & Systems Biology, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY, USA. greenbab@mskcc.org.

^# Contributed equally.

PMID: 35641605
PMCID: PMC9200628
DOI: 10.1038/s41586-022-04879-8

Published Erratum

Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness

David Hoyos et al. Nature. 2022 Jun.

. 2022 Jun;606(7914):E5.

doi: 10.1038/s41586-022-04879-8.

Authors

Affiliations

¹ Computational Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Swim Across America Laboratory and Ludwig Collaborative, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. roz4022@med.cornell.edu.
³ Department of Medicine, Weill Cornell Medical College, New York, NY, USA. roz4022@med.cornell.edu.
⁴ Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. roz4022@med.cornell.edu.
⁵ Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA. roz4022@med.cornell.edu.
⁶ Swim Across America Laboratory and Ludwig Collaborative, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷ Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁸ Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁰ Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.
¹¹ Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
¹² Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹³ Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁴ Experimental and Translational Immunology, Health Technology, Technical University of Denmark, Lyngby, Denmark.
¹⁵ Physiology, Biophysics & Systems Biology, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY, USA.
¹⁶ Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁷ Adaptive Biotechnologies, Seattle, WA, USA.
¹⁸ David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁹ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²⁰ Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
²¹ Swim Across America Laboratory and Ludwig Collaborative, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org.
²² Department of Medicine, Weill Cornell Medical College, New York, NY, USA. merghout@mskcc.org.
²³ Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org.
²⁴ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. merghout@mskcc.org.
²⁵ Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ, USA.
²⁶ Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
²⁷ Computational Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. greenbab@mskcc.org.
²⁸ Physiology, Biophysics & Systems Biology, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY, USA. greenbab@mskcc.org.

^# Contributed equally.

PMID: 35641605
PMCID: PMC9200628
DOI: 10.1038/s41586-022-04879-8

No abstract available

PubMed Disclaimer

Erratum for

Fundamental immune-oncogenicity trade-offs define driver mutation fitness.
Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade KC, Bajorin DF, Bandlamudi C, Callahan MK, Funt SA, Hadrup SR, Holm JS, Rosenberg JE, Shah SP, Vázquez-García I, Weigelt B, Wu M, Zamarin D, Campitelli LF, Osborne EJ, Klinger M, Robins HS, Khincha PP, Savage SA, Balachandran VP, Wolchok JD, Hellmann MD, Merghoub T, Levine AJ, Łuksza M, Greenbaum BD. Hoyos D, et al. Nature. 2022 Jun;606(7912):172-179. doi: 10.1038/s41586-022-04696-z. Epub 2022 May 11. Nature. 2022. PMID: 35545680 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness

Affiliations

Author Correction: Fundamental immune-oncogenicity trade-offs define driver mutation fitness

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources